Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027. Multiple scaled-up batches of CXU™ material met predefined specifications, supporting both regulatory testing and future commercial production. RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) — Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), […]